5.21
Mannkind Corp stock is traded at $5.21, with a volume of 2.13M.
It is down -0.76% in the last 24 hours and down -6.96% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$5.25
Open:
$5.24
24h Volume:
2.13M
Relative Volume:
0.92
Market Cap:
$1.58B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
104.20
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
+1.17%
1M Performance:
-6.96%
6M Performance:
-15.97%
1Y Performance:
+17.08%
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MNKD
Mannkind Corp
|
5.21 | 1.58B | 248.37M | 11.74M | 18.24M | 0.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-10-25 | Initiated | Wedbush | Outperform |
Dec-20-24 | Initiated | Wells Fargo | Overweight |
Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Sep-09-24 | Resumed | Leerink Partners | Outperform |
Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
Oct-10-23 | Initiated | Wedbush | Outperform |
May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-24-19 | Initiated | Oppenheimer | Outperform |
Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
May-14-19 | Initiated | BTIG Research | Buy |
Mar-04-19 | Initiated | SVB Leerink | Outperform |
Feb-22-19 | Initiated | SVB Leerink | Outperform |
Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
Oct-10-17 | Initiated | H.C. Wainwright | Buy |
Oct-06-17 | Reiterated | Maxim Group | Buy |
Aug-11-17 | Initiated | Maxim Group | Buy |
May-10-16 | Reiterated | Piper Jaffray | Underweight |
May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
May-11-15 | Reiterated | MLV & Co | Hold |
Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com
MAC Lung Disease Market Statistics Expected to Experience Major - openPR
MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025 - Nasdaq
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - Yahoo Finance
AllPennyStocks.com News: Companies Looking Towards Future Revenue with New Diabetes Therapies - ACCESS Newswire
Commit To Purchase MannKind At $3, Earn 13.3% Using Options - Nasdaq
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Non- Tuberculous Mycobacterial Infections Market on Track - openPR
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ - MSN
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus.com
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha
MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call Transcript - Insider Monkey
MannKind: Q4 Earnings Snapshot - mySA
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Re - GuruFocus.com
MannKind Corp Q4 Earnings: EPS Meets Estimates at $0.03, Revenue Surpasses Expectations at $77 Million - GuruFocus.com
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Mannkind stock gains amid Q4 report, business update - MSN
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind (MNKD) Q4 Earnings Meet Estimates - Yahoo Finance
Earnings call transcript: MannKind Q4 2024 beats EPS forecast, stock jumps - Investing.com
MannKind earnings beat by $0.05, revenue topped estimates - Investing.com
MannKind shares move 4% higher on strong revenue growth By Investing.com - Investing.com South Africa
MannKind shares move 4% higher on strong revenue growth - Investing.com
MANNKIND CORP SEC 10-K Report - TradingView
MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Ex - GuruFocus.com
MannKind: Q2 Earnings Snapshot -August 07, 2024 at 08:09 am EDT - Marketscreener.com
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 - Yahoo Finance
MannKind Sets Stage for 2024 Performance Review: CEO and CFO to Unveil Full Year Results - StockTitan
MannKind (MNKD) Expected to Announce Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage on MannKind (NASDAQ:MNKD) - MarketBeat
MannKind To Present At Oppenheimer Healthcare Life Sciences Conference; Webcast At 11:20 AM ET - Nasdaq
An Analysis of Mannkind Corp (MNKD)’s Potential Price Growth - Knox Daily
MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wedbush - Defense World
Investing in Fortuna Mining Corp (FSM) Is Getting More Attractive - Knox Daily
MannKind Co. (NASDAQ:MNKD) Shares Sold by Calamos Advisors LLC - MarketBeat
There is no doubt that Mannkind Corp (MNKD) ticks all the boxes. - SETE News
MannKind to Present at Upcoming Investor Conferences - Yahoo Finance
MNKD Shares Experience Surge in Value - Knox Daily
MannKind Executives Set for Strategic Presentations at Elite Healthcare Investment Forums - StockTitan
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
(02/03/25) Top Picks 2025: MannKind (MNKD) - Moneyshow.com
MNKD Makes Notable Cross Below Critical Moving Average - Nasdaq
MannKind Co. (NASDAQ:MNKD) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
MannKind Co. (NASDAQ:MNKD) Given Consensus Rating of “Buy” by Brokerages - Defense World
Cantor Fitzgerald Estimates MannKind FY2025 Earnings - Defense World
MannKind (NASDAQ:MNKD) Shares Down 3.1%Should You Sell? - MarketBeat
MannKind Co. (NASDAQ:MNKD) Sees Large Drop in Short Interest - MarketBeat
International Assets Investment Management LLC Has $86,000 Position in MannKind Co. (NASDAQ:MNKD) - Defense World
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):